DOI: http://dx.doi.org/10.18203/2394-6040.ijcmph20192831

A prevalence study of ocular manifestations in HIV positive patients on highly active anti-retroviral therapy

Hemal S. Hothi, Neepa R. Gohil, Nilesh V. Parekh, Sagar S. Patel

Abstract


Background: Among 40 million cases worldwide, 50-75% of patients have at least one ocular manifestation in their lifetime. Many of ocular infections are treatable with therapeutic agents. Ocular manifestations invariably reflect systemic disease and can be the initial manifestations of HIV in many cases. Understanding of ocular sequel of HIV infection can lead to the early diagnosis and effective treatment. This study emphasizes on the need of developing a specific ophthalmic examination for the management of ocular manifestations in HIV infected patients.

Methods: Cross sectional and observational study of 100 HIV positive participants on HAART were done irrespective of presence or absence of ocular symptoms. Participants were examined for complete ocular examination. Prevalence find out using chi-square test, find p values and ensuring statistical significance.

Results: In our study, prevalence of ocular manifestation in HIV positive patients receiving HAART was 39%. Out of them, 20% adnexal involvement, 28% anterior segment involvement, 33% posterior segment involvement, 11% neuro-ophthalmic abnormality, 4% orbital involvement were present. 76% patients belonged to WHO clinical stage 2 and 3. 51% had CD4+ T cell counts <200 cells/µl.

Conclusions: Posterior segment followed by anterior segment are the most commonly encountered ocular manifestations of HIV infection. Low CD4 count is good predictor for ocular manifestations in HIV positive patients. Higher WHO stage is also directly related with the severity of the ocular symptoms. Routine baseline ophthalmic screening to all HIV positive patients are necessary to prevent ocular morbidity.


Keywords


HIV, HAART, Ocular involvement, CD4 count, WHO stage

Full Text:

PDF

References


Dutta, LC. Acquired immunodeficiency syndrome and the eye. Chapter 144. In: Modern Ophthalmology. Volume 1. 3rd Edition. New Delhi: Jaypee Brothers; 2005: 1127-1141.

Sihota R, Tandon R. Ocular manifestations of systemic disorders. Chapter 32. In: Parson’s diseases of the Eye. 20th edition. New Delhi: Elsivier; 2007: 504-507.

Labh RK, Chaudhary M, Shah DN. Eye changes among HIV positive patients on antiretroviral therapy in Nepal. Nepal J Ophthalmol. 2016;8(15):62-70.

Biswas J, Joseph A, Raizada S, Kumarsamy N, Solomon S. Ophthalmic manifestations of human immunodeficiency virus (HIV) infection in India. Indian J Ophthalmol. 1999;47:87-93.

Kempen J. Medical management of human immunodeficiency virus infection. Indian J Ophthalmol. 2008;56:385-90.

Murthy GVS. The socioeconomic impact of human immunodeficiency virus/ acquired immune-deficiency syndrome in India and its relevance to eye care. Indian J Ophthalmol. 2008;56:395-7.

Venkatesh K. Impact of highly active antiretroviral therapy on ophthalmic manifestations in HIV/AIDS. Indian J Ophthalmol. 2008;56:391-3.

Goldberg DE, Smithen LM, Angelilli A, Freeman WR. HIV-associated retinopathy in the HAART era. Retina. 2005;25(5):633-49.

Shah SU, Kerkar SP, Pazare AR. Evaluation of ocular manifestations and blindness in HIV/AIDS patients on HAART in a Tertiary Care Hospital in Western India. Br J Ophthalmol. 2009;93:88-90.

Jabs DA, Van Natta ML, Holbrook JT, Kempen JH, Meinert CL, Davis MD. Longitudinal study of the ocular complications of AIDS: Ocular diagnoses at enrollment. Ophthalmlogy. 2007;114:780-6.

Mansour AM. Neuro-ophthalmic findings in Acquired immunodeficiency syndrome. J Clin Neuroophthalmol. 1990;10:167-74.

Jabs DA, Holbrook JT, Mark L, Van Natta ML, Clark R, Jacobson MA, et al. Risk Factors for Mortality in Patients with AIDS in the Era of Highly Active Antiretroviral Therapy. Ophthalmology. 2005;112:771.